Transcatheter aortic valve replacement in cancer patients with chest radiation therapy: Risks and outcomes.
Abstract
e24020 Background: Transcatheter aortic valve replacement (TAVR) is a widely adopted treatment for severe aortic stenosis, but outcomes in cancer survivors with prior chest radiation therapy (C-XRT) remain uncertain. This study compares the clinical outcomes of TAVR between patients with a history of C-XRT and those without prior radiation exposure (control group). Methods: Patients with prior chest radiation therapy (C-XRT) were compared to a control group without radiation exposure to evaluate key clinical endpoints. For each endpoint, odds ratios (OR) and 95% confidence intervals (CI) were determined, and heterogeneity was analyzed using the I² statistic. A p-value of <0.05 was considered statistically significant. Results: Nine studies were included in the meta-analysis, encompassing 3083 C-XRT and 8891 control patients. Patients with prior C-XRT showed significantly higher long-term mortality (OR 1.84, 95% CI [1.08, 3.13], p=0.02) compared to controls. Other outcomes, including access-related vascular complications, Acute Kidney Injury, Congestive heart failure, major bleeding, need for pacemaker, short-term mortality, and stroke, did not demonstrate significant differences between the groups. Conclusions: Cancer survivors with prior chest radiation therapy undergoing TAVR may experience higher long-term mortality compared to patients without radiation exposure. However, no significant differences were observed in other major outcomes. These findings suggest that while TAVR is a viable treatment for C-XRT patients, long-term risks require further investigation to optimize patient selection and management strategies. Outcomes. Outcome OR 95% Confidence Interval P value Access related vascular complications 1.12 [0.85, 1.48] 0.43 Acute kidney injury 0.54 [0.20, 1.50] 0.24 Congestive heart failure 1.38 [0.88, 2.17] 0.16 Long term mortality 1.84 [1.08, 3.13] 0.02 Major bleeding 0.96 [0.78, 1.17] 0.67 Need for pacemaker 1.05 [0.88, 1.26] 0.57 Short term mortality 1.66 [0.97, 2.84] 0.06 Stroke 1.25 [0.74, 2.11] 0.39
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (12)
Saad Farooq
Montefiore Saint Luke's Cornwall Hospital, Newburgh, NY
Muneeb Khawar
King Edward Medical University, Lahore, Pakistan
Umad Ali
King Edward Medical University, Lahore, Pakistan
Syed Abdullah Shah
Mirza Muhammad Hadeed khawar
Services Institute of Medical Sciences, Lahore, Pakistan
Awon Muhammad
King Edward Medical University, Lahore, Pakistan
Hannan Saeed
KEMU, Lahore, Pakistan
Sardar Muhammad Imran Khan
NUMS, Rawalpindi , Pakistan
Abdul Qadeer
Mobeen Zaka Haider
West Virginia University, Morgantown, WV
Mohammad Hamza
Albany Medical Center, Aldan, Pennsylvania, United States
Robert W. Kirchoff
Mayo Clinic Hospital, Pheonix, AZ